Lexicon Pharmaceuticals (LXRX) Income from Continuing Operations (2010 - 2026)
Lexicon Pharmaceuticals' (LXRX) quarterly Income from Continuing Operations came in at 5296000.0 in Q1 2026, up 81.51% year-on-year from 2917698.99 in Q1 2025, and up 68.5% on a QoQ basis from 16811000.0 in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 17 years of Income from Continuing Operations data on file, last reported at 5296000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 81.51% year-over-year to 5296000.0 in Q1 2026; TTM through Mar 2026 was 42966000.0, a 77.74% increase from a year earlier, with the FY2025 full-year figure at 60556000.0, up 90.2% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 5296000.0, up from 16811000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for LXRX reached as high as 4172000.0 in Q2 2025 and fell as low as 68255000.0 in Q3 2024.
- Historically, Income from Continuing Operations has averaged 34565529.41 across 5 years, with a median of 31223000.0 in 2022.
- Across the five-year window, Income from Continuing Operations tumbled 146.74% in 2023 and surged 92.75% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 31223000.0 in 2022, then tumbled by 67.05% to 52158000.0 in 2023, then increased by 26.14% to 38522000.0 in 2024, then soared by 56.36% to 16811000.0 in 2025, then soared by 68.5% to 5296000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 5296000.0 in Q1 2026, 16811000.0 in Q4 2025, and 16687000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Lexicon Pharmaceuticals | 979.13 Mn | 808.47 Mn | 20.99 Mn | -5.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.30 Mn |
| Dec 31, 2025 | -16.81 Mn |
| Sep 30, 2025 | -16.69 Mn |
| Jun 30, 2025 | -4.17 Mn |
| Mar 31, 2025 | -28.65 Mn |
| Dec 31, 2024 | -38.52 Mn |
| Sep 30, 2024 | -68.26 Mn |
| Jun 30, 2024 | -57.57 Mn |
| Mar 31, 2024 | -50.28 Mn |
| Dec 31, 2023 | -52.16 Mn |
| Sep 30, 2023 | -59.96 Mn |
| Jun 30, 2023 | -51.38 Mn |
| Mar 31, 2023 | -32.70 Mn |
| Dec 31, 2022 | -31.22 Mn |
| Sep 30, 2022 | -24.30 Mn |
| Jun 30, 2022 | -26.15 Mn |
| Mar 31, 2022 | -23.52 Mn |
| Dec 31, 2021 | -25.43 Mn |
| Sep 30, 2021 | -23.13 Mn |
| Jun 30, 2021 | -18.14 Mn |